4.5 Review

Progress in pharmacological research of chemokine like factor 1 (CKLF1)

Journal

CYTOKINE
Volume 102, Issue -, Pages 41-50

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.cyto.2017.12.002

Keywords

Chemokine like factor 1; C19 peptide; C27 peptide; CCR4; Allergic diseases; Autoimmune diseases

Funding

  1. National Natural Science Foundation of China [81603315, 81274122, U1402221, 81260650]
  2. National High-Tech R&D Programme (863 Program) [2012AA020303]
  3. Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study [BZ0150]
  4. Key Research and Development Project of Hunan Province [2015SK2029-1]
  5. Scientific Research Foundation of the Higher Education Institutions of Hunan Province [15091]
  6. CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-12M-1-004]

Ask authors/readers for more resources

Currently, the research of chemokines has penetrated into many fields of life science. A new kind of chemokines, chemokine like factor 1 (CKLF1), which is cloned through suppression subtractive hybridisation (SSH) technology is expressed widely in human body, especially in the lung and peripheral blood leukocytes. CKLF1 has a broad spectrum of chemotaxic activity for many cells, such as lymphocytes, macrophages, bone marrow cells, nerve cells and so on. In addition, CKLF1 also stimulates the regeneration of skeletal muscle cells in vivo. Collecting data derived from our and other laboratories show that CKLF1 has an important relationship with allergic diseases, autoimmune diseases, tumors, cardio-cerebrovascular diseases and so on. Therefore, there be an important theoretical purport and applied value to make a summary of pharmacological progress of CKLF1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available